Praxis Precision Advances CNS Disorder Therapies
Company Announcements

Praxis Precision Advances CNS Disorder Therapies

Praxis Precision Medicines ( (PRAX) ) has shared an announcement.

Praxis Precision Medicines is advancing its CNS disorder therapies, with promising developments in its late-stage drugs: relutrigine for developmental and epileptic encephalopathies, ulixacaltamide for essential tremor, and vormatrigine for epilepsy. The company is expanding its EMBOLD study and planning new trials, supported by strong financials and a focus on precision medicine. These efforts highlight significant progress towards potentially transformative treatments in the neurological space.

See more insights into PRAX stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyPraxis Precision reports Q3 EPS ($2.75), consensus ($1.99)
TheFlyPraxis Precision price target raised to $163 from $143 at Oppenheimer
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App